Daiichi could be rewarded for persisting with Vanflyta
A front-line trial yields a positive result two years after the drug got a US complete response letter.
ASN 2021 – Glaxo’s daprodustat delivers
But whether data on the novel anaemia pill are clean enough to dispel wider FDA toxicity concerns is hard to call.
Triple meeting – low-profile assets boost Merus and Bicycle
Merus regains some lost pride while Bicycle rides to even greater heights.
Astellas readies roxadustat for launch
But winning EU approval for the novel anaemia pill was not straightforward, the Japanese firm says.
Roche U-turns and Adaptimmune wins
A low-key cancer discovery alliance sees Roche abandoning its earlier opposition to cell therapies.
Novartis pushes on with iscalimab after transplant disappointment
The autoimmune target CD40 has yielded few hits despite years of research, but a few companies are keeping the faith.
